Condition: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) · Albuminuria · Sponsor: University of Illinois at Chicago
Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).
This description comes directly from the study's public registry record.
Santosh L Saraf, MD · 312-996-5680 · ssaraf@uic.edu
Anand Srivastave, MD
Always discuss trial participation with your own doctor first.
| University of Illinois Chicago, Sickle Cell Center | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07175051